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patients or for patients with CHD, and patients of control group
were in routine clinical practice. All patients were observed
during 12 months. Economic efﬁciency in both cases was evalu-
ated on the basis of “cost of illness” and “cost-effectiveness”
analysis. RESULTS: In hypertensive patients we received the
following results. The cost-efﬁciency ratio for decreasing blood
pressure on 1% was $216.6 in the treatment group and $1179 in
the control group. The results of patients’ education in CHD
patient were the following: The cost-efﬁciency ratio for decreas-
ing angina attacks frequency on 1% was S974 in treatment group
and 2838$ in control group. The cost-efﬁciency ratio for decreas-
ing cholesterol on 1% was $2857 in the treatment group and
S4365 in the control group. The cost-efﬁciency ratio for decreas-
ing blood pressure on 1% was $1606 in the treatment group and
$9316 in the control group. CONCLUSION: Educational pre-
ventive technologies for patients with cardiovascular diseases are
cost-effective over a one-year period.
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OBJECTIVE: Diagnosis of coronary artery disease (CAD) in
China using coronary angiography (CA) is challenging due to
high disease prevalence and limited resources. It has been esti-
mated that up to 50% of Chinese patients are negative for CAD
upon CA. Coronary CT Angiography (CTA) may provide an
opportunity to minimize unnecessary invasive diagnostic proce-
dures and increase patient access to diagnosis of CAD in a
cost-effective manner. This study was conducted to evaluate the
potential costs and efﬁciency of utilizing CTA in combination
with CA to optimize diagnosis and care of patients with sus-
pected CAD in China. METHODS: We conducted a cost-
consequences analysis from the perspective of Fuwai Hospital in
Beijing. We developed a decision-analytic model comparing a
diagnostic strategy of CA only with a strategy of CTA in com-
bination with CA for patients with low to moderate pre-test
probability (based on Duke Clinical Score) of signiﬁcant disease.
All CA-positive patients were assumed to receive percutaneous
coronary intervention (PCI). CTA diagnostic accuracy data and
cost estimates were obtained from Fuwai Hospital and other
inputs were derived from the published literature. RESULTS: In
the base-case analysis, assuming a CAD prevalence of 39%
(range 18–64%) in the low to moderate risk patient population,
utilization of CTA in combination with CA lead to a cost savings
of $559 (USD) per patient (range $680–$416) compared to the
CA only diagnosis strategy. The hospital cost per diagnosis of
CAD was $12,483 (CTA + CA) (range $14,197–$11,900) and
$13,418 (CA only) (range $17,406–$12,100), and the propor-
tion of catheter lab diagnoses leading to PCI increased from 39%
(range 18–64%) to 73% (range 48–88%). CONCLUSION: Our
study suggests that CTA implementation in China could optimize
the patient population that undergoes invasive CA procedures
and provide cost-savings for Chinese hospitals.
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OBJECTIVE: To examine how found ‘obesity paradox’—a para-
doxical decrease in morbidity and mortality with increasing BMI
in subjects with cardiovascular disease (CVD)—relates to health
care-expenditures using Medical Expenditure Panel Survey
(MEPS). METHODS: We performed cross-sectional analyses of
11,385 adults from the 2005 MEPS, a national survey of nonin-
stitutionalized civilian population in the United States. Subjects
with CVD (coronary heart disease, myocardial infarction, stroke,
and hypertension) were determined from self-reports. Mean
expenditures per capita were estimated for NIH BMI categories
(under, normal, overweight, obese I, II, and III) using a two-part
exponential conditional model (ECM) adjusted for age, race,
wage, occupation, type of health insurance, degree level, and
smoking status. The ﬁrst part of the model was logistic regression
to predict the probability of incurring any expenditures. For the
second part, we used ECM since the log-scale expenditure data
was not leptokurtotic and was heteroscedastic. We performed
Box-Cox test and Park test to ﬁnd the link function and distri-
bution family. Average expenditures in 2005 U.S. dollars were
calculated by multiplying each person’s probability of incurring
any expense and expenditures. RESULTS: About 67% of sub-
jects with CVD (N = 2596) and 65% of subjects without CVD
(N = 8789) were overweight or obese. Using gamma distribution
with log link function, mean expenditures in CVD-group by BMI
categories were $3247, $3040, $3098, $2966, $3500, and $3375
(p = non-signiﬁcant). Those in subjects without CVD were
$1857, $2327, $2389, $2534, $3179, and $3783 (p < 0.001).
Age, smoking status, and Medicare were associated with
expenditures in CVD-group. CONCLUSION: Health care-
expenditures did not signiﬁcantly differ among BMI categories in
subjects with CVD whereas health care-expenditures were
increasing with BMI in subjects without CVD. This could be due
to the inﬂuence of CVD-care costs across weight categories in
CVD-group. We did not ﬁnd a obesity paradox in health care-
expenditures in subjects with CVD.
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OBJECTIVE: Few cost-of-illness studies in stroke have examined
the incremental impact of comorbid condition(s). The aim of this
study was to assess the costs of stroke management attributable
to stroke and comorbid conditions using data from the Medicare
program in the United States (U.S.). METHODS: Medicare
beneﬁciaries diagnosed with hemorrhagic (HS) and ischemic (IS)
stroke from 2002–2005 were identiﬁed from a 5% random
sample of Medicare outcomes and care database. Direct costs
were assessed from the perspective of the Medicare program.
Descriptive and multivariate analyses were performed. Data were
analyzed from one year prior to the index event through four
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years following that event. RESULTS: A total of 10,335 patients
were identiﬁed; 8444 with IS and 1891 with HS. Increases in
medical costs during the four year post index period were as
follows for HS patients: without co-morbidities, $14,745; with
hypertension, $22,667; with hypertension plus type 2 diabetes
(T2D), $29,662; with hypertension plus congestive heart failure
(CHF), $26,768; with hypertension plus T2D plus CHF,
$34,302. For IS patients, these costs were $17,000 for IS-only
patients, but ranged from $21,344–$30,987 for IS patients with
other comorbidities. Results from multivariate analyses sup-
ported the validity of the descriptive statistics. CONCLUSION:
Comorbidities/risk factors contribute substantial incremental
costs to the already high economic burden of both HS and IS
stroke.
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OBJECTIVE: The morbidity of acute myocardial infarction
(AMI) is remarkable in Hungary, therefore it is inevitable to
understand the disease burden more accurately. Our aim was to
assess the burden of AMI in Hungary between 2003 and 2005.
We studied how much burden AMI patients impose on the
ﬁnancer (National Health Insurer Fund Administration—
NHIFA) in the inpatient and outpatient care and we estimated
the size of indirect social costs, too. METHODS: We extracted
the data of ‘new’ AMI patients (ICD-10: I21 main diagnosis but
not treated with the same diagnosis in the previous 24 months)
hospitalized in May 2003 from the database of the ﬁnancer. We
analyzed inpatient treatment costs of these patients in the period
of 12 months before the AMI and in the following ﬁrst and
second 12 months. Data were distributed by sex and age (age
groups: 25–44, 45–64, over 65). Other costs were estimated
after expert consultations. RESULTS: Average health insurance
costs of AMI’s active hospital care in the ﬁrst 12 months are
generally higher in females as in males; €1905.2 vs. €1564.4 (65
and over), €1716.4 vs. €1557.6 (45–64) and €918.0 vs. €962.4
(25–44). The burden in the chronic care is €60–160 per patient
in the ﬁrst year, which is similar to the active care costs in the
23rd to 24th months after the AMI (€88–216). CONCLUSION:
NHIFA was estimated to spend 17.6 million Euros on direct
health care on behalf of the nearly 12,000 annual AMI patients
in the ﬁrst 12 months. Avoiding one AMI could save €1380–
2260 (depending on gender and age) direct health care cost in
the ﬁrst 12 months. According to our estimate, the annual indi-
rect costs of AMI exceed €3.36 million (€711.3/patient) in the
working age group.
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OBJECTIVE: To examine variation in outlier payments across
U.S. hospitals and the extent which variation is explained by
patient and hospital factors, including quality of care.
METHODS: Using the national Medicare claims database for
2002, we examined outlier payments in patients undergoing
coronary artery bypass grafting (CABG) (n = 165,226). We
then categorized hospitals performing these procedures accord-
ing to their outlier payment rates. Using multiple logistic regres-
sion, we explored the relationships between hospital outlier
payment rates, patient case mix and hospital quality, as
reﬂected by risk-adjusted mortality rates. RESULTS: The pro-
portion of patients associated with outlier payments was 14%
(CABG). Average outlier payments were considerable: $24,000
per patient, costing Medicare more than half a billion dollars.
Risk factors for outlier payments were race and admission
acuity. Higher hospital and surgeon volumes and teaching
status were associated with lower rates of outlier payments.
There was a negative correlation between risk-adjusted mortal-
ity rates and outlier payments. The proportion of outlier pay-
ments was greater than 20 percent. Measurable patient and
hospital factors explained a small proportion of variation
across hospitals. CONCLUSION: Outlier payments in CABG
are an important component of medical costs with inpatient
surgery. Although explained in part by quality, reasons for wide
variation in outlier payments across hospitals remain to be
clariﬁed.
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OBJECTIVE: We evaluated the likelihood and cost of adverse
events (AE) by choice of acute conversion therapy for atrial
ﬁbrillation (AF) in hospitalized patients. METHODS: We
extracted Premier Perspective(tm) 2004–2005 discharges with
primary AF diagnosis and treatment with electric conversion
(EC) or IV anti-arrhythmic agent (AA; either amiodarone, ibutil-
ide or procainamide). We estimated odds ratios and inpatient
costs attributable to any AE, hypotension AE, or dysrhythmia AE
based on treatment, adjusting for comorbid, demographic and
hospital-speciﬁc factors. RESULTS: Out of 74,072 discharges
initially treated with EC (32%), amiodarone (49%), ibutilide
(11%) or procainamide (8%), approximately 28% (20,808) had
a treatment-related AE. Of these, 24% had hypotension and
37% experienced dysrhythmia. Odds ratios for any AE were
signiﬁcantly higher when initial treatment was amiodarone vs.
EC (OR; 95% CI) (1.24; 1.20–1.29), amiodarone vs. procaina-
mide (1.36; 1.27–1.46) and amiodarone vs. ibutilide (1.58; 1.48–
1.68). A similar pattern was observed for hypotension AE. Initial
treatment with EC increased the likelihood of dysrhythmia AE
vs. amiodarone (1.23; 1.16–1.30), ibutilide (1.21; 1.11–1.33)
and procainamide (1.29; 1.16–1.44). Adjusted costs for dis-
charges with any AE were signiﬁcantly higher vs. discharges
without AE (P < 0.0001). AE among patients receiving an AA
had the highest cost impact, contributing an average of $2702
in additional adjusted costs. Hypotension and dysrhythmia AE
among patients receiving AA were associated with $1232 and
$1054 in additional adjusted costs, respectively (P < 0.0001).
Among patients receiving EC, any AE, dysrhythmia and hypoten-
sion AE were associated with $2128 (P < 0.0001), $1655
(P < 0.0001) and no signiﬁcant (P = 0.21) increase in costs,
respectively. CONCLUSION: The likelihood of AE is associated
with choice of initial AF therapy. Patients initially treated with
amiodarone have the highest likelihood of AE, particularly
hypotension AE; those treated initially with EC have a higher
likelihood of dysrhythmia AE. Incremental costs attributable to
AE are substantial in this population.
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